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Abstract
MUC17 is a type 1 membrane-bound glycoprotein that is mainly expressed in the digestive tract. Recent studies have
demonstrated that the aberrant overexpression of MUC17 is correlated with the malignant potential of pancreatic ductal
adenocarcinomas (PDACs); however, the exact regulatory mechanism of MUC17 expression has yet to be identified. Here,
we provide the first report of the MUC17 regulatory mechanism under hypoxia, an essential feature of the tumor
microenvironment and a driving force of cancer progression. Our data revealed that MUC17 was significantly induced by
hypoxic stimulation through a hypoxia-inducible factor 1a (HIF1a)-dependent pathway in some pancreatic cancer cells (e.g.,
AsPC1), whereas other pancreatic cancer cells (e.g., BxPC3) exhibited little response to hypoxia. Interestingly, these low-
responsive cells have highly methylated CpG motifs within the hypoxia responsive element (HRE, 59-RCGTG-39), a binding
site for HIF1a. Thus, we investigated the demethylation effects of CpG at HRE on the hypoxic induction of MUC17.
Treatment of low-responsive cells with 5-aza-29-deoxycytidine followed by additional hypoxic incubation resulted in the
restoration of hypoxic MUC17 induction. Furthermore, DNA methylation of HRE in pancreatic tissues from patients with
PDACs showed higher hypomethylation status as compared to those from non-cancerous tissues, and hypomethylation was
also correlated with MUC17 mRNA expression. Taken together, these findings suggested that the HIF1a-mediated hypoxic
signal pathway contributes to MUC17 expression, and DNA methylation of HRE could be a determinant of the hypoxic
inducibility of MUC17 in pancreatic cancer cells.
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Introduction
Pancreatic cancer is one of the most aggressive forms of cancer.
Because of its aggressive growth and metastatic properties, the
overall survival rate of patients with pancreatic cancer is 3–5% [1].
Avascular morphology is a major characteristic of pancreatic
cancer, resulting in poor blood and oxygen supply. Consequently,
pancreatic cancer contains tumor cells that are at low oxygen
tensions, a condition called hypoxia. Accumulating evidence
indicates that the hypoxic tumor microenvironment is intimately
correlated with solid tumor characteristics including invasion,
metastasis, and poor response to anticancer therapies [2,3]. In this
regard, hypoxia-inducible factor 1a (HIF1a) has been identified as
a key regulator of the hypoxic response, activating various cancer-
related genes such as VEGF, CAIX, and GLUT1.
Mucins are heavily O-glycosylated proteins found in the mucus
layer, and they are differentially expressed at the cell surface of
many epithelia. They are responsible for the physical properties of
mucus gels and are involved in epithelial cell protection and
maintenance of the local molecular microenvironment [4,5,6,7].
By contrast, there is also increasing evidence that mucins are
aberrantly expressed in various cancers, and they have been
implicated in malignant transformation as well as tumor cell
proliferation, survival, invasion, and metastasis [8,9,10]. In this
context, recent studies revealed that certain membrane-bound
mucins are sufficient for inducing the epithelial-to-mesenchymal
transition and thereby represent attractive targets for anticancer
treatment [11,12].
The MUC17 glycoprotein was characterized as a membrane-
bound mucin [13]. RNA blot analysis indicated that MUC17 is
mainly expressed in the digestive tract, including the duodenum,
ileum, and transverse colon [13,14]. Under physiological condi-
tions, it has been suggested that endogenous MUC17 plays an
important role in cell restitution processes and contributes to
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colon–mucosal protection [15,16]. Moniaux et al. reported that
MUC17 was aberrantly expressed in pancreatic ductal adenocar-
cinomas (PDACs) compared with its lack of expression in normal
pancreas or pancreatitis [17]. Furthermore, Hirono et al. also
reported that MUC17 is an independent prognostic factor
associated with lymph node metastasis in PDACs [18]. These
findings suggest that MUC17 may have an important role in
pancreatic cancer progression. Regarding the regulatory mecha-
nism of MUC17, our previous study suggested that the epigenetic
changes, including CpG-DNA methylation and histone modifica-
tions at H3-K9 in the MUC17 proximal promoter are key
determinants of MUC17 expression [19]. However, it is still
unclear what kinds of transcriptional factors are recruited to the
MUC17 promoter and involved in the regulation of MUC17
expression.
In the present study, we provide the first evidence describing the
regulatory mechanism of MUC17 in the hypoxic tumor micro-
environment. Our results show that MUC17 is induced by HIF1a
mediating hypoxic response, and the specific DNA methylation
determines the hypoxic inducibility of MUC17 in pancreatic
cancer cells.
Materials and Methods
Ethics statement
Human pancreatic tumor tissues were obtained from Ka-
goshima University Hospital, and written informed consent was
obtained from all study participants. This study was approved by
the ethical committee of Kagoshima University Hospital.
Pancreatic cancer cell lines and human tissue samples
The human pancreatic carcinoma cell lines AsPC1, BxPC3,
HPAFII, and PANC1 were purchased from the American Type
Culture Collection (Manassas, VA, USA). BxPC3 and AsPC1 cells
were cultured in RPMI-1640 medium (Sigma, St. Louis, MO,
USA.). HPAFII cells were cultured in Eagle’s minimum essential
medium (Sigma). PANC1 cells were cultured in D-MEM (Sigma).
All media were supplemented with 10% fetal bovine serum
(Invitrogen) and 100 U/mL penicillin/100 g/mL streptomycin
(Sigma). Hypoxic culture conditions were achieved with a multi-
gas incubator containing a gas mixture composed of 94% N2, 5%
CO2, and 1% O2 (ASTEC, Japan). All experiments were
performed at least three times unless otherwise noted.
RNA extraction and RT-PCR
Total RNA was extracted using the RNeasy Mini Kit (Qiagen,
Valencia, CA, USA) and quantified using a NanoDrop ND-1000
spectrophotometer (NanoDrop, Wilmington, DE, USA). For RT-
PCR, the obtained mRNA was reverse-transcribed to cDNA with
the High Capacity RNA-to-cDNA Kit (Applied Biosystems, Foster
City, CA, USA) according to the manufacturer’s instructions. The
primers for the subsequent PCR are shown in Table S1. PCR was
performed with the AmpliTaq Gold Fast PCR Master Mix
(Applied Biosystems) following the manufacturer’s protocol.
Protein extraction and Western blotting
Cells were cultured on 6-cm dishes under hypoxic conditions for
their designated times. Total cell lysates were prepared using
RIPA buffer containing protease inhibitor cocktail (Nacalai
Figure 1. MUC17 expression is enhanced by hypoxia. (A) AsPC1 cells were cultured under hypoxic conditions (1% O2) for the indicated times.
MUC17 mRNA expression was examined by RT-PCR at each time point. (B) AsPC1 cells were cultured under normoxic or hypoxic conditions for the
indicated times. Cell lysates were probed with anti-MUC17, HIF1a, and a-tubulin antibodies by Western blot analysis. The intensities of the bands
were quantitated by densitometric scanning, and the ratio of MUC17 to a-tubulin expression is shown under each band as the relative intensity
compared with that obtained in normoxic AsPC1 cells. (C) MUC17 promoter activity was measured by a Dual-Luciferase Reporter Assay. After
transfection of the MUC17 reporter plasmid, AsPC1 cells were incubated under normoxic or hypoxic conditions for 24 h. Cell lysates were assayed
using a luciferase assay kit in a Tristar multimode microplate reader LB941 (Berthold Technologies). Transformation efficiency was normalized on the
basis of Renilla luciferase activity. The promoter activity under normoxic conditions was given a value of 1. P values were determined using the
Student’s t-test. * P,0.05.
doi:10.1371/journal.pone.0044108.g001
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Tesque, Japan). After quantification by the BCA assay (Thermo
Scientific), equal amounts was resolved by 3–8% SDS-PAGE and
electrotransferred onto PVDF membranes. For MUC17 expres-
sion analysis, protein lysates were resolved on 2% agarose gels
containing SDS and passively transferred onto PVDF membranes
and incubated overnight at room temperature. Membranes were
blocked with 1% skim milk/PBST for 2 h and subjected to the
standard immunodetection procedure using specific primary
antibodies. The primary antibodies were as follows: anti-human
MUC17 (rabbit pAb, 1:1000, generated by one of the authors, Dr.
Surinder K. Batra, University of Nebraska Medical Center,
Omaha, NE, USA); anti-human HIF1a (mouse mAb, 1:1000,
H1alpha67, Novus Biologicals), and anti-human a-tubulin (mouse
mAb, DM1A, Sigma).
RNA interference
For RNA interference (RNAi) experiments, HIF1A expression
was silenced using On-Target plus siRNA (Dharmacon) according
to the manufacturer’s instruction. On-Target plus siControl non-
targeting siRNA was used as a control. AsPC1 cells were seeded in
6-cm dishes, and at 50260% confluency, they were transfected
with 13.6 nmol/L siRNA using Lipofectamine RNAiMAX
(Invitrogen).
Dual-Luciferase Reporter Assay
The 59 flanking sequence (2687 to +53) of human MUC17 was
amplified using genomic DNA isolated from AsPC1 cells. The
PCR fragment was digested with NheI and XhoI and cloned into
the pGL4.17 vector (Promega). To generate HRE mutants of the
human MUC17 promoter, a QuikChange Lightning Site-Directed
Mutagenesis Kit was utilized (Stratagene). The primer sets are
shown in Table S1. For the dual luciferase reporter assay, AsPC1
cells were seeded in a 24-well plate at a density of 16105 cells/well
and transiently transfected with 75 ng of the luciferase reporter
plasmid using JetPEI (Polyplus Transfection) according to the
manufacturer’s protocol. Then, the luciferase activity in the total
cell lysates was assayed after 24 h using the Dual-Luciferase
Reporter Assay System (Promega) in a Tristar multimode
microplate reader LB 941 (Berthold Technologies). The Renilla
luciferase reporter gene expressed in a pGL4.74 vector was
simultaneously transfected as an internal control.
Chromatin immunoprecipitation
The chromatin immunoprecipitation (ChIP) assay was per-
formed using a Shearing-ChIP kit and a OneDay ChIP kit
(Diagenode, Philadelphia, PA, USA) according to the manufac-
turer’s instructions. In brief, the nucleoprotein complexes were
sonicated to reduce the sizes of DNA fragments from 300 to
Figure 2. Hypoxic induction of MUC17 is dependent on HIF1a in AsPC1 cells. (A) After the transfection of HIF1A siRNAs, AsPC1 cells were
cultured under normoxia (N) or hypoxia (H) for 24 h. The level of mRNA was measured by RT-PCR. (B) Cell lysates from AsPC1 cells treated with HIF1A
siRNAs were immunoblotted with the indicated antibodies. a-tubulin served as a loading control. (C) The densities of the acquired bands from
Western blotting analysis were quantified and expressed as relative fold increases compared with that obtained from mock cells under hypoxic
culture conditions. ns, not significant. * P,0.05, ** P,0.005.
doi:10.1371/journal.pone.0044108.g002
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500 bp by using a Bioruptor (Cosmo Bio). One microgram of
normal mouse IgG was used as the negative control, and mouse
anti-human HIF1a antibody was used for each immunoprecipi-
tation. Immunoprecipitated DNA was amplified by PCR as
described previously. The ChIP primers were designed to target
the HRE site of the MUC17 promoter. The primers for the
subsequent PCR are shown in Table S1. The PCR conditions
were 95uC for 5 min, 34 cycles at 96uC for 5 s, 59uC for 5 s, and
68uC for 7 s, and a final extension reaction at 72uC for 1 min. The
amplified products were subjected to 1.0% agarose gel electro-
phoresis.
DNA methylation analysis
For CpG demethylation analysis, AsPC1 cells were incubated
with 1 mM 5-azadC (Sigma) for 7 days. At the end of the
treatment, DNA and protein were extracted for methylation-
specific PCR (MSP) and Western blotting. DNA extraction and
MSP were performed according to standard methods. In brief,
total DNA from cell lines and tissues were extracted using a
DNeasy Tissue System (Qiagen). Bisulfite modification of the
genomic DNA (2 mg) was performed using an Epitect Bisulfite Kit
(Qiagen), and equal amounts of modified DNA were amplified by
PCR using the AmpliTaq Gold Fast PCR Master Mix (Applied
Biosystems). The specificity of MSP primers is largely influenced
by the thermodynamic characteristics of the 39 end of the
proposed primer. Thus, we set the cytidine residue of CpG within
HRE as the 39 end of the MSP primer. The U primer is designed
for amplification of sodium bisulfite converted DNA in an
unmethylated condition, while the M primer is specific for sodium
bisulfite converted methylated DNA. The HRE-targeted primer
pairs are shown in Table S1. The PCR conditions were 95uC for
10 min, 40 cycles at 96uC for 5 s, 59uC for 5 s, and 68uC for 5 s,
and a final extension reaction at 72uC for 1 min. The amplified
products were subjected to 1.0% agarose gel electrophoresis.
To further investigate the correlation of MUC17 expression
with the methylation status in biological samples, pancreatic tumor
tissues were obtained from the surgically resected pancreatic
specimens of 10 patients with PDAC. Normal pancreatic tissues
were obtained from the same patients from areas distant from the
tumor. All tissue samples were stored at 280uC until use. To
conduct MSP and RT-PCR, total DNA and RNA were isolated
from the tissues and analyzed as described previously. The bands
obtained from MSP and RT-PCR were quantified by Image J soft
ware, and the relative level of unmethylation in each sample was
calculated as an index of unmethylation status using the equation
(%) =U/(U+M). The correlation of MUC17 mRNA expression
with the methylation status of HRE was analyzed using Spear-
man’s test.
Statistical Analysis
In the luciferase reporter and ChIP assays, the statistical
differences were determined using a two-sided Student’s t-test. To
investigate the correlation between HRE methylation status and
MUC17 expression in tissue samples, Spearman’s test was
Figure 3. Hypoxia enhances the recruitment of HIF1a to HRE and activates MUC17 transcription. (A) Binding of HIF1a to chromatin was
confirmed by a ChIP assay. AsPC1 cells were cultured under normoxia or hypoxia for 24 h. PCR was performed with specific primers covering HRE. (B)
The densities of the acquired bands in panel (A) were quantified using Image J (NIH) and normalized to Input included in each experiment. (C) To
evaluate the transactivation activity of HIF1a through HRE, a dual luciferase assay was conducted. AsPC1 cells were transfected with wild-type or HRE
mutant MUC17 promoter constructs under hypoxic conditions for 24 h. P values were determined using Student’s t-test. ns, not significant. * P,0.01,
** P,0.001.
doi:10.1371/journal.pone.0044108.g003
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performed using the statistical software R version 2.12.2. P,0.05
was considered significant.
Results
Expression of MUC17 is increased under hypoxia in
pancreatic cancer cells
To examine the effect of hypoxic exposure on MUC17
expression, we cultured human pancreatic cancer cells AsPC1
under hypoxic culture conditions (1% O2) for 2 days. In RT-PCR
analysis, the expression of MUC17 and CAIX, a hypoxic marker,
was significantly increased, whereas the HIF1a mRNA levels were
stable under hypoxic conditions, confirming the previously
reported posttranscriptional regulation of HIF1a [20]. Western
blotting was also employed to examine the MUC17 protein level,
and it revealed a prominent induction of MUC17 and HIF1a
expression in a time-dependent manner (Figure 1A and 1B). To
date, HIF1a is known as a key regulator of hypoxic response in
many cancers. HIF1a binds to hypoxia responsive element (HRE,
59-RCGTG-39), a binding site for HIF1a, and transactivates many
hypoxia-responsive genes including VEGF, GLUT1, and CAIX.
We conducted sequence analysis of the approximately 3.0-kb
MUC17 promoter with MatInspector software (Genomatix) and
found a putative HRE (+37/+41) in the proximal promoter region
of MUC17. Thus, we hypothesized that MUC17 overexpression
under hypoxic conditions is mediated by HIF1a. To examine the
effect of hypoxia on the transcriptional activity of the MUC17
promoter, we constructed an MUC17 promoter–luciferase
reporter vector containing the HRE site. Under hypoxic
conditions, AsPC1 cells transfected with this construct exhibited
significantly increased reporter activity (Figure 1C), suggesting that
the enhancement of MUC17 expression under hypoxic conditions
is due to an increase in transcriptional activity.
Hypoxic induction of MUC17 is regulated by the HIF1a-
dependent signal pathway
In order to investigate whether HIF1a is really involved in the
hypoxic induction of MUC17, we examined the effect of HIF1a
silencing on the hypoxic MUC17 induction in AsPC1 cells by
using siRNAs. Under hypoxia, control siRNA had no effect on
transcription of MUC17, HIF1a, CAIX, and ß-actin. On the
contrary, treatment with siRNAs targeting HIF1a led to a
prominent decrease of hypoxic MUC17 induction as well as
CAIX (Figure 2B). The same result was observed at the protein
level (Figure 2B), indicating the involvement of HIF1a in hypoxic
MUC17 induction.
Hypoxia enhances the recruitment of HIF1a to HRE and
activates MUC17 transcription
To assess the involvement of HIF1a in MUC17 transcriptional
regulation, we performed ChIP assays. The result revealed that the
anti-HIF1a antibody significantly enriched the MUC17 promoter
fragments harboring HRE under hypoxic conditions but not
under normoxic conditions (Figure 3A and 3B). Further, we tested
whether HRE was indeed essential for hypoxia-inducing MUC17
transactivation. Reporter vectors harboring mutations at the HRE
site were constructed and transfected into AsPC1 cells under
hypoxic conditions. As shown in Figure 3C, cells transfected with
either mutant vectors exhibited significantly reduced transactiva-
tion compared with that of the wild-type promoter construct-
Figure 4. Methylation status of HRE within the MUC17 proximal promoter region. (A) Differential expression pattern of MUC17 induced by
hypoxic exposure in pancreatic cancer cell lines. Each pancreatic cell line was cultured under normoxic (N) or hypoxic (H) conditions. Level of mRNA
was determined by RT-PCR at each time point. (B) The human MUC17 gene promoter sequence, which spans positions2687 to +302 with respect to
the transcription start site. The numbers of the CpG sites are underlined. The HRE site contains the CpG site (No. 13).
doi:10.1371/journal.pone.0044108.g004
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transfected cells, indicating the essential role of the HRE site in the
hypoxic MUC17 induction.
Differential expression pattern of MUC17 induced by
hypoxia in various pancreatic cancer cell lines
Furthermore, we evaluated whether the hypoxic induction of
MUC17 is a universal event in pancreatic cancer cells. Additional
cell lines (BxPC3, HPAFII, and PANC1) were cultured under
hypoxic conditions for 2 days, and mRNA expression levels were
monitored. The results revealed that MUC17 expression levels in
AsPC1 and HPAFII cells were significantly increased under
hypoxic conditions. In contrast, only a faint increase was observed
in BxPC3 and PANC1 cells (Figure 4A). In this context, we
recently reported that DNA hypomethylation is a key factor for
MUC17 expression in pancreatic cancer (Figure 4B). Interestingly,
AsPC1 and HPAFII cells, which exhibited prominent MUC17
induction under hypoxia, displayed an almost completely un-
methylated HRE (No. 13) within the MUC17 promoter, whereas
BxPC3 and PANC1 cells had highly methylated HREs [19]. Thus,
we hypothesized that the DNA methylation status of HRE
determines MUC17 induction in response to hypoxia.
DNA methylation status of HRE determined the hypoxia
inducibility of MUC17 expression
To investigate the involvement of DNA methylation of HRE in
MUC17 expression under hypoxic conditions, we treated BxPC3
and PANC1 cells with 5-AzadC (a DNA demethylating agent) for
7 days, and the cells were incubated for another 24 h under
normoxia or hypoxia. First, we confirmed the demethylation effect
of 5-AzadC treatment on HRE by MSP (Figure 5A). Then, we
examined the MUC17 expression in cells treated with 5-AzadC
under hypoxic conditions, resulting in the restoration of MUC17
expression only in cells treated 5-AzadC treatment under hypoxia
(Figure 5B).
MUC17 expression correlates with hypomethylation at
HRE within the promoter region
Furthermore, to evaluate the biological significance of HRE
methylation in MUC17 expression, we examined MUC17
expression and methylation status in normal and pancreatic
tumor tissues from patients with PDACs by RT-PCR and MSP,
respectively. Consistent with the previous reports [17,18], MUC17
mRNA and protein are overexpressed in PDAC (Figure 6A and
B). In the MSP analysis using 10 paired PDAC samples (non-
cancerous tissues; n = 10, cancerous tissues; n = 10), unmethylated
signals were significantly observed in tissues with PDAC as
compared to those from non-cancerous tissues (Two-tailed
Student’s t-test, P = 0.007). We also investigated the correlation
between MUC17 mRNA expression and the methylation status of
HRE. The level of MUC17 mRNA was strongly correlated to the
hypomethylation status of HRE within the MUC17 promoter in
pancreatic cancer (Figure 6C).
Discussion
Recent studies have identified human MUC17, which is
overexpressed in PDACs, as an independent prognostic factor of
lymph node metastasis [17,18]. Although little is known about the
functional role of MUC17 in cancer, understanding the regulatory
mechanism of MUC17 can be a key step in developing new
strategies for cancer diagnosis and treatment.
In the present study, we investigated the hypoxic regulation of
MUC17 in pancreatic cancer cells. Our results demonstrated that
MUC17 is significantly induced by hypoxia in a time-dependent
manner, and this upregulation is directly mediated by HIF1a.
Moreover, the use of four cell lines with different MUC17 hypoxic
inducibilities allowed us to propose a model for the epigenetic
regulation of MUC17 in pancreatic cancer. We propose that DNA
methylation of HRE inhibits HIF1a-mediated MUC17 transacti-
vation in cells with low MUC17 hypoxic inducibility, whereas
progressive hypomethylation of HRE allows a prominent increase
in MUC17 expression under hypoxic conditions in cells with high
hypoxic inducibility. There is increasing evidence that the
methylation of CpG sites in promoter regions affects the induction
of gene expression by HIF1a, presumably by limiting the access of
transcriptional factors to cis-acting elements [21,22]. As shown in
Figure 6, hypomethylation of HRE within the MUC17 promoter
is a frequent event in the pancreatic tissues of patients with PDAC.
Although further studies are needed to elucidate the other factors
involved in MUC17 expression, this could explain why MUC17 is
overexpressed in pancreatic cancer. Regarding the lack of CAIX
induction in PANC1 cells, it has been demonstrated that CAIX
expression is, at least in part, regulated by site-specific CpG
hypomethylation at 274 bp in the promoter in renal cell
carcinoma and other cancer cell types [23,24,25]. Therefore, this
response may also be affected by the DNA methylation status of
HRE within the CAIX promoter.
There are some implications for considering the functional role
of MUC17 in cancer development. In solid tumors, because of the
unrestricted proliferation of cancer cells and inadequate vascular-
ization, oxygen starvation (hypoxia) and nutrient deprivation are
Figure 5. Methylation status of the HRE site determines the
sensitivity of MUC17 to HIF1a-induced transactivation. (A)
Demethylation of CpG sites in the MUC17 promoter in BxPC3 and
PANC1 cells after 1 mM 5-azadC treatment. MUC17-negative/low cell
lines were treated with or without 5-azadC for 7 days. The methylation
status of the MUC17 promoter harboring HRE was examined by MSP.
The PCR products labeled M (methylated) were amplified by
methylation-specific primers, and those labeled U (unmethylated) were
amplified by primers specific for unmethylated DNA. (B) Restoration of
MUC17 expression in pancreatic cancer cell lines by 5-azadC treatment.
Cells were treated with or without 5-azadC for 7 days. During the last
24 h, each group was cultured under normoxic (N) or hypoxic (H)
conditions. MUC17 expression was examined by Western blotting.
doi:10.1371/journal.pone.0044108.g005
Hypoxic Induction of MUC17 in Pancreatic Cancer
PLOS ONE | www.plosone.org 6 September 2012 | Volume 7 | Issue 9 | e44108
recognized as essential features of the tumor microenvironment
and a driving force of cancer progression. Recently, it has been
reported that MUC1, which is also identified as a hypoxia-
inducible mucin, could promote autophagy, providing a survival
advantage in the low glucose-stressed microenvironment through
the suppression of glucose deprivation-induced increases of ROS
levels in colon cancer [26]. In addition, it also has been reported
that stable transfection of small hairpin RNA targeting endoge-
nous MUC17 in colon cancer LS174T cells resulted in reduced
cell aggregation, reduced cell–cell adherence and migration, and
increased susceptibility to apoptosis [15]. These findings indicate
that MUC17 might have some functions, including cell migration,
invasion, resistance to apoptosis and adaptation to stressed
microenvironments in pancreatic cancer progression.
Alterations of DNA methylation are one of the most remarkable
epigenetic changes in human cancer. The accumulating evidence
suggests that aberrant DNA methylation is frequently observed
even in the early and precancerous stages of human carcinogenesis
and it may be an indicator of carcinogenetic risk, an early
diagnostic marker for cancer, and a biological predictor of cancer
malignancies [27,28]. It has been reported that epigenetic
modifications including DNA methylation largely contribute to
Figure 6. MUC17 expression is correlated with the hypomethylation of HRE within the MUC17 promoter in tissues from patients
with PDAC. (A) MUC17 mRNA expression and the HRE methylation status in the normal pancreas (N) and pancreatic tumor tissues (T) was examined
by RT-PCR and MSP, respectively. (B) Representative immunohistochemical staining data for MUC17 in a patient with PDAC. Scale bar, 100 mm. (C)
Correlation of MUC17 mRNA expression and the HRE methylation status was analyzed by Spearman’s test. The densities of the acquired bands were
quantified using Image J, and the relative amount of unmethylation in each sample was calculated as an index of the aberrant unmethylation status
using the equation (%) =U/(U+M).
doi:10.1371/journal.pone.0044108.g006
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the expression of human mucin family genes in cancer
[19,29,30,31,32,33,34]. Zhu et al. have reported an aberrant
increase in both the expression and hypomethylation of MUC4
during PanIN-PDAC progression [35]. In addition, we developed
a novel method for detecting DNA methylation patterns called
MSE, which enabled the detection of altered methylation in
pancreatic juice and revealed the significantly different methyla-
tion patterns in the MUC1 promoter between intraductal papillary
mucinous neoplasm and PDAC, indicating its potential diagnostic
use [36]. Although further studies are needed to clarify the
clinicopathological importance and precise mechanisms of
MUC17 expression, these findings raise the possibility that the
methylation status of the MUC17 promoter is an epigenetic
marker for the diagnosis of carcinogenic risk and the prediction of
outcomes of patients with PDAC. Taken together, our study
demonstrates for the first time that MUC17 expression is
enhanced by the HIF1a-mediated hypoxic response and that
DNA methylation of HRE is a key determinant of the hypoxic
inducibility of MUC17 in pancreatic cancer. In the future, the
significance of these findings in pancreatic cancer pathogenesis will
be explored.
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